RxDoctor Payments Data

Jessica Cassady, MD

Internal Medicine · Cincinnati, OHNPI 1083807762

Payments from drug & device makers

$6,313in general payments, 2019–2025

Across 325 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$667
  • Novo Nordisk$560
  • Pfizer$549
  • Lilly USA, LLC$495
  • GSK$339
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,313100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,313 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$28,525
Medicare patients
78
Services billed
348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban33$24,888
TrulicityDulaglutide13$24,512
MounjaroTirzepatide22$22,762
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$18,820
FarxigaDapagliflozin Propanediol19$18,467
EliquisApixaban11$18,114
JardianceEmpagliflozin15$16,234
RybelsusSemaglutide17$16,186
Soliqua 100-33Insulin Glargine/Lixisenatide17$15,046
Atorvastatin Calcium242$1,766
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen33$1,538
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,513
Levothyroxine Sodium112$1,500
Fentanyl11$1,479
Novolog FlexpenInsulin Aspart11$1,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$495$47,27535 claims
Johnson & JohnsonXarelto$77$24,88833 claims
GSKTrelegy Ellipta$339$18,82014 claims
AstraZenecaFarxiga$667$18,46719 claims
PfizerEliquis$549$18,11411 claims
Boehringer IngelheimJardiance$109$16,23415 claims
Novo NordiskRybelsus$560$16,18617 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$45$15,04617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →